StockNews.AI
PYXS
StockNews.AI
96 days

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

1. Pyxis Oncology presents strong preclinical data for micvotabart pelidotin. 2. Phase 1 trial data expected in late 2025; supportive for R/M HNSCC. 3. Combination study with pembrolizumab targets multiple tumor types. 4. Cash runway sufficient through 2026, allowing ongoing clinical development. 5. Net loss increased to $21.2 million, impacting investor sentiment.

13m saved
Insight
Article

FAQ

Why Bullish?

The positive preclinical data suggests significant potential for micvotabart pelidotin, bolstering confidence in its efficacy and future data reports, similar to how early promising data often lead to stock price increases in biotech firms, such as AVEO Pharmaceuticals when they reported favorable data for tivozanib.

How important is it?

The article highlights critical data and upcoming milestones that situate Pyxis favorably within its competitive landscape, impacting investor strategies around the stock.

Why Short Term?

The expected preliminary data releases in late 2025 could trigger immediate market reactions, as seen with other clinical-stage companies that experience price movements following key trial announcements.

Related Companies

MRKAVEONVS
May 15, 2025 07:00 ET  | Source: Pyxis Oncology - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients in second half of 2025 - Expected cash runway through data milestones and into second half of 2026 BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2025, and provided a business update. “We are enthusiastic about the progress we are making with micvotabart pelidotin, particularly our recent preclinical data that validate its unique three-pronged mechanism of action and indicate that MICVO monotherapy may be eliciting immune responses in previously unresponsive tumors,” said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology. “Our focus remains on delivering durable and efficacious therapies for patients with recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors, building on the tremendous potential of our next generation ADC. We look forward to reporting data from our ongoing Phase 1 trials evaluating MICVO as a monotherapy and in combination with pembrolizumab later this year.” Pipeline Updates Pyxis Oncology presented promising preclinical data at the 2025 American Association for Cancer Research Annual Meeting supporting the unique three-pronged mechanism of action of MICVO driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death. These data further reinforce the potential patient benefit of MICVO as a monotherapy and in combination with an anti-PD-1 therapy. MICVO demonstrated broad anti-tumor activity across ten solid tumor indications in PDX models, attributed to EDB+FN target expression, proteolytic activity for MICVO linker cleavage and tumor responsiveness to the cytotoxic Auristatin0101 payload.Differential gene expression analysis enabled identification of gene signatures associated with anti-tumor activity.Upregulation of certain proteases may contribute to increased linker cleavage and subsequent increased MICVO activity, supporting hypothesis for extracellular mechanism.Combining a mouse analog of MICVO with anti-PD-1 therapy inhibited EMT6 tumor growth and improved survival. The Company expects to report preliminary data from the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 clinical trial evaluating MICVO in 2L and 3L R/M HNSCC patients who have received prior platinum and PD-1 inhibitor therapy in the second half of 2025 and 2L and 3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in the first half of 2026. R/M HNSCC continues to be an area of high medical need despite improvements in treatment options. Pyxis Oncology anticipates selecting a dose of MICVO in the ongoing Phase 1/2 combination study of micvotabart pelidotin and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors by mid-year 2025 and reporting preliminary data from the trial in the second half of 2025. First Quarter 2025 Financial Results As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.Research and development expenses were $17.0 million for the quarter ended March 31, 2025, compared to $13.0 million for the quarter ended March 31, 2024. The increase was primarily due to increased clinical trial-related expenses related to monotherapy and combination therapy of micvotabart pelidotin, increase in preclinical and translation work to support clinical development of micvotabart pelidotin and increased manufacturing of drug product and drug substance.General and administrative expenses were $5.9 million for the quarter ended March 31, 2025, compared to $8.2 million for the quarter ended March 31, 2024. The decrease was primarily due to lower stock-based compensation costs, lower corporate insurance costs and decrease in legal, professional and consulting fees.Net loss was $21.2 million, or ($0.35) per common share, for the quarter ended March 31, 2025, compared to $3.3 million, or ($0.06) per common share, for the quarter ended March 31, 2024. Net loss for the quarter ended March 31, 2024 included total revenues of $16.1 million related to the settlement agreement with Novartis for sale of royalty rights of Beovu® for a one-time amount of $8.0 million and Novartis agreed to forgo its right to reclaim royalties previously paid of $8.1 million to us and Apexigen. Excluding non-cash stock-based compensation expense, the net loss for the quarter ended March 31, 2025 was $17.5 million, compared to net income of $1.1 million for the quarter ended March 31, 2024. As of May 14, 2025, the outstanding number of shares of Common Stock of Pyxis Oncology was 61,947,665. About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors. To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn. Forward Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed with SEC on May 15, 2025, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. Pyxis Oncology ContactPamela Connealy CFO and COO ir@pyxisoncology.com  PYXIS ONCOLOGY, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss(In thousands, except share and per share amounts)(Unaudited)   Three Months Ended March 31,   2025  2024 Revenues      Royalty revenues $—  $8,146 Sale of royalty rights  —   8,000 Total revenues  —   16,146 Costs and operating expenses      Cost of revenues  —   475 Research and development  17,044   13,029 General and administrative  5,870   8,247 Total costs and operating expenses  22,914   21,751 Loss from operations  (22,914)  (5,605)Other income, net:      Interest and investment income  1,241   1,550 Sublease income  515   799 Total other income, net  1,756   2,349 Net loss $(21,158) $(3,256)Net loss per common share - basic and diluted $(0.35) $(0.06)Weighted average shares of common stock outstanding - basic and diluted  61,048,948   51,289,284   PYXIS ONCOLOGY, INC.Condensed Consolidated Balance Sheets(In thousands, Unaudited)   March 31, 2025  December 31, 2024 Assets      Current assets:      Cash and cash equivalents $12,759  $19,473 Marketable debt securities, short-term  92,673   107,458 Restricted cash  1,472   1,472 Prepaid expenses and other current assets  4,967   4,037 Total current assets  111,871   132,440 Property and equipment, net  9,403   9,899 Intangible assets, net  2,544   2,600 Operating lease right-of-use asset  12,049   12,242 Total assets $135,867  $157,181 Liabilities and Stockholders’ Equity      Current liabilities:      Accounts payable $2,846  $4,859 Accrued expenses and other current liabilities  10,076   11,371 Operating lease liabilities, current portion  1,508   1,450 Total current liabilities  14,430   17,680 Operating lease liabilities, net of current portion  18,254   18,650 Financing lease liabilities, net of current portion  80   100 Total liabilities  32,764   36,430 Commitments and contingencies      Stockholders’ equity:      Preferred stock  —   — Common stock  62   60 Additional paid-in capital  487,706   484,077 Accumulated other comprehensive income  49   170 Accumulated deficit  (384,714)  (363,556)Total stockholders’ equity  103,103   120,751 Total liabilities and stockholders’ equity $135,867  $157,181 

Related News